161 related articles for article (PubMed ID: 20818793)
1. Natalizumab dosage suspension: are we helping or hurting?
West TW; Cree BA
Ann Neurol; 2010 Sep; 68(3):395-9. PubMed ID: 20818793
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab drug holiday in multiple sclerosis: poorly tolerated.
Killestein J; Vennegoor A; Strijbis EM; Seewann A; van Oosten BW; Uitdehaag BM; Polman CH
Ann Neurol; 2010 Sep; 68(3):392-5. PubMed ID: 20661928
[TBL] [Abstract][Full Text] [Related]
3. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
4. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
[TBL] [Abstract][Full Text] [Related]
6. Observations during an elective interruption of natalizumab treatment: a post-marketing study.
Borriello G; Prosperini L; Marinelli F; Fubelli F; Pozzilli C
Mult Scler; 2011 Mar; 17(3):372-5. PubMed ID: 21148264
[TBL] [Abstract][Full Text] [Related]
7. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X
Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
10. Evolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosis.
Castela E; Lebrun-Frenay C; Laffon M; Rocher F; Cohen M; Leccia NC; Bahadoran P; Lacour JP; Ortonne JP; Passeron T
Arch Dermatol; 2011 Jan; 147(1):72-6. PubMed ID: 20855675
[TBL] [Abstract][Full Text] [Related]
11. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
[TBL] [Abstract][Full Text] [Related]
13. The role of natalizumab in the treatment of multiple sclerosis.
Coyle PK
Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab use in pediatric multiple sclerosis.
Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
[TBL] [Abstract][Full Text] [Related]
15. A giant MS plaque mimicking PML during natalizumab treatment.
Twyman C; Berger JR
J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
17. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
Putzki N; Yaldizli O; Bühler R; Schwegler G; Curtius D; Tettenborn B
Eur Neurol; 2010; 63(2):101-6. PubMed ID: 20090344
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
20. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
Miravalle A; Jensen R; Kinkel RP
Arch Neurol; 2011 Feb; 68(2):186-91. PubMed ID: 20937940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]